Telix Completes BiPASS Enrollment and Aligns With FDA
MELBOURNE, Australia and INDIANAPOLIS, September 2, 2026 Telix Pharmaceuticals Limited has completed enrollment of 350 patients in its Phase...
nuclear medicine
Advertisement
Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Spectrum Dynamics Launches VERITON-CT 400 Enhancement
MORGES, Switzerland, July 20, 2026 Spectrum Dynamics Medical has announced the launch of the All-Energy Enhancement for its FDA-cleared,...
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Advertisements
Telix Completes Phase 3 Enrollment for Illuccix in Japan
MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...
Telix Opens Australia’s First Integrated Radiopharmaceutical Facility for Cancer Care
MELBOURNE, Australia & INDIANAPOLIS, Ind., July 16, 2026 Telix has officially opened Telix Manufacturing Solutions North Melbourne (TMSNM), Australia’s...
Sanyou Bio Partners Baiyunshan Xihe for Radiopharma Innovation
SHANGHAI & GUANGZHOU, China, July 4, 2026 Sanyou Biopharmaceutical Co., Ltd. (Sanyou Bio) and Guangzhou Baiyunshan Xihe Health Pharmaceutical...
C Ray Therapeutics Secures Key Radiopharmaceutical License
CHENGDU, China, June 2026 C Ray Therapeutics (Chengdu) Co., Ltd. announced that it has officially obtained a Radiopharmaceutical Manufacturing...
Teva Highlights Long-Term AUSTEDO Success in Tardive Dyskinesia Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...
Advertisement
